Role of novel biomarkers in diabetic cardiomyopathy

Kumrić, Marko; Kurir, Tina Tičinović; Borovac, Josip Anđelo; Božić, Joško

doi:10.4239/wjd.v12.i6.685

Cited by 21 publications

(20 citation statements)

References 199 publications

(190 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diabetic cardiomyopathy (DCM), an under-recognized and lethal complication of diabetes, is commonly defined as cardiomyopathy in patients with diabetes mellitus (DM) in the absence of coronary artery disease, hypertension or dyslipidemia [26]. Among many others, diminished GLUT4 expression and increased CD36 expression, which lead to additional myocardial metabolism shift from glucose to free fatty acid (FFA) oxidation and consequent metabolic inflexibility, represent the pathophysiological mechanisms underlying this complex clinical entity [27].…”

Section: Role Of Adropin In Metabolism and Diverse Pathologiesmentioning

confidence: 99%

Role of Adropin in Cardiometabolic Disorders: From Pathophysiological Mechanisms to Therapeutic Target

et al. 2021

Self Cite

View full text Add to dashboard Cite

Although a large amount of data supports the crucial role of endothelial dysfunction (ED) in cardiovascular diseases (CVDs), there is a large bench-to-bedside chasm between basic and clinical research of ED, limiting the implementation of these findings in everyday clinical settings. Hence, it is important to further investigate the pathophysiological mechanisms underlying ED and find modalities that will alleviate its clinical implementation. Adropin, a highly conserved peptide hormone secreted primarily by the liver, recently emerged as an important regulatory component of the vascular endothelium. Specifically, the vasoprotective role of adropin is achieved mainly by affecting endothelial NO synthesis. Thus, in this review, we aimed to summarize the current knowledge regarding the role of adropin in physiological processes and address the protective role of adropin in endothelium with consequent implications to CV pathologies. We focused on data regarding the role of adropin in the clinical setting, with concurrent implications to future clinical use of adropin. Studies suggest that plasma levels of adropin correlate with indices of ED in various pathologies and enhanced disease progression, implying that adropin may serve as a useful biomarker of ED in the upcoming future. On the other hand, despite notable results with respect to therapeutic potential of adropin in preliminary experiments, further well-designed studies are warranted in order to establish if adropin might be beneficial in this setting.

show abstract

Section: Role Of Adropin In Metabolism and Diverse Pathologiesmentioning

confidence: 99%

Role of Adropin in Cardiometabolic Disorders: From Pathophysiological Mechanisms to Therapeutic Target

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is characterized by early impaired diastolic function, myocardial hypertrophy, myocardial fibrosis, and systolic dysfunction, and it eventually results in heart failure [64]. DC is currently considered to be a cause of high mortality in patients with diabetes, and there is no effective treatment [65]. More and more studies indicate that ER stress is involved in DC [66][67][68].…”

Section: Hydrogen Sulfide Improves Diabetic Cardiomyopathy By Regulat...mentioning

confidence: 99%

Hydrogen Sulfide Plays an Important Role by Regulating Endoplasmic Reticulum Stress in Diabetes-Related Diseases

Zhao

Liu

Yang

et al. 2022

IJMS

View full text Add to dashboard Cite

Endoplasmic reticulum (ER) plays important roles in protein synthesis, protein folding and modification, lipid biosynthesis, calcium storage, and detoxification. ER homeostasis is destroyed by physiological and pharmacological stressors, resulting in the accumulation of misfolded proteins, which causes ER stress. More and more studies have shown that ER stress contributes to the pathogenesis of many diseases, such as diabetes, inflammation, neurodegenerative diseases, cancer, and autoimmune diseases. As a toxic gas, H2S has, in recent years, been considered the third most important gas signal molecule after NO and CO. H2S has been found to have many important physiological functions and to play an important role in many pathological and physiological processes. Recent evidence shows that H2S improves the body’s defenses to many diseases, including diabetes, by regulating ER stress, but its mechanism has not yet been fully understood. We therefore reviewed recent studies of the role of H2S in improving diabetes-related diseases by regulating ER stress and carefully analyzed its mechanism in order to provide a theoretical reference for future research.

show abstract

“…Although plasma inflammatory biomarkers (e.g., interleukin-6 and C-reactive protein) and macroalbuminuria [132], as well as red blood cell distribution width (RDW) [133], have been shown to be predictors of HF their ability to predict HF in the individual patient with DM is limited. Although it has been recently suggested that lncRNA, sST2 and galectin-3 may be promising biomarkers for diabetic cardiomyopathy detection as their plasma/serum levels correlate with the early stages of diabetic cardiomyopathy, further validation studies are necessary [50]. Thus, there is an urgent need for diagnostic approaches that incorporate biomarkers unique to the diabetic cardiomyopathic process [134].…”

Section: Gaps In Knowledge and Future Perspectivesmentioning

confidence: 99%

Diabetes Mellitus and Heart Failure

Triposkiadis

Xanthopoulos

Bargiota

et al. 2021

JCM

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a major risk factor for new-onset heart failure (HF) and vice versa. The pathogenesis of new-onset HF in DM is complex and has been largely attributed to the toxic cardiovascular effects of hyperglycemia and relevant metabolic abnormalities (diabetic cardiomyopathy) as well as the frequently coexisting morbidities such as hypertension (HTN), coronary artery disease (CAD), and diabetic nephropathy. In patients with type 1 DM (T1DM), HF develops in the setting of a dysregulated immune response, whereas in most patients with type 2 DM (T2DM), against a background of overweight/obesity. HF prevention in DM is feasible with rigorous treatment of cardiovascular risk factors and selective antidiabetic agents. Conversely, development of new-onset T2DM in HF (cardiogenic DM) is common and has been attributed to an increase in the resistance to insulin, especially in the skeletal muscle, liver, and adipose tissue as well as in diminished insulin secretory response to hyperglycemia by pancreatic β-cells. Cardiogenic DM further deteriorates cardiac dysfunction and adversely affects outcome in HF. Novel lifesaving medications employed in HF management such as sacubitril/valsartan and sodium glucose cotransporter 2 inhibitors (SGLT-2i) have a favorable metabolic profile and lower the incidence of cardiogenic diabetes. Whether mitigation of cardiogenic DM should be a treatment target in HF deserves further investigation.

show abstract

Role of novel biomarkers in diabetic cardiomyopathy

Cited by 21 publications

References 199 publications

Role of Adropin in Cardiometabolic Disorders: From Pathophysiological Mechanisms to Therapeutic Target

Role of Adropin in Cardiometabolic Disorders: From Pathophysiological Mechanisms to Therapeutic Target

Hydrogen Sulfide Plays an Important Role by Regulating Endoplasmic Reticulum Stress in Diabetes-Related Diseases

Diabetes Mellitus and Heart Failure

Contact Info

Product

Resources

About